TakeAim
TakeAim Leukemia: A Phase 1/2A, Open Label Dose Escalation and Expansion Study of Orally Administered CA-4948 as a Monotherapy in Patients With Acute Myelogenous Leukemia or Myelodysplastic Syndrome and in Combination With Azacitidine or Venetoclax
Filters
Save & Share
Clear Filters
Location
Explore options near your center - or near your patient's home.
MDS Centers of Excellence
Diagnosis
Purpose of Trial
Filter and find trials based on their purpose.
Risk Level
Enter this patient's risk level (IPSS-R / IPSS-M).
Near Add Your Location
Sort by
Center of Excellence
- Accepting patients
Center of Excellence
Dana-Farber Cancer Institute
Boston, MA
- Accepting patients
Center of Excellence
- Accepting patients
Novant Health Forsyth Cancer Institute - Bethesda Court
Winston-Salem, NC
- Accepting patients
Center of Excellence
- Accepting patients
Center of Excellence
- Accepting patients
Center of Excellence
Ohio State University Comprehensive Cancer Center
James Cancer Hospital and Solove Research Institute
Columbus, OH
- Accepting patients
509 hidden based on your filters. Show All
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print a patient-friendly report to share with your patient.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.